Epigral Ltd vs Tatva Chintan Pharma Chem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 18, 2026

Key Highlights

The Latest Trading Price of Epigral Ltd is ₹ 856.45 as of 18 Mar 15:30 . The P/E Ratio of Epigral Ltd changed from 16 on March 2022 to 22.9 on March 2025 . This represents a CAGR of 9.38% over 4 yearsThe P/E Ratio of Tatva Chintan Pharma Chem Ltd changed from 53.4 on March 2022 to 278.3 on March 2025 . This represents a CAGR of 51.09% over 4 years The Market Cap of Epigral Ltd changed from ₹ 4045 crore on March 2022 to ₹ 8191 crore on March 2025 . This represents a CAGR of 19.29% over 4 yearsThe Market Cap of Tatva Chintan Pharma Chem Ltd changed from ₹ 5115 crore on March 2022 to ₹ 1588 crore on March 2025 . This represents a CAGR of -25.35% over 4 years The revenue of Epigral Ltd for the Dec '25 is ₹ 602.68 crore as compare to the Sep '25 revenue of ₹ 589.1 crore. This represent the growth of 2.31% The revenue of Tatva Chintan Pharma Chem Ltd for the Dec '25 is ₹ 133.07 crore as compare to the Sep '25 revenue of ₹ 124.52 crore. This represent the growth of 6.87% The ebitda of Epigral Ltd for the Dec '25 is ₹ 108.26 crore as compare to the Sep '25 ebitda of ₹ 133.8 crore. This represent the decline of -19.09% The ebitda of Tatva Chintan Pharma Chem Ltd for the Dec '25 is ₹ 27.22 crore as compare to the Sep '25 ebitda of ₹ 23.22 crore. This represent the growth of 17.23% The net profit of Epigral Ltd changed from ₹ 85.87 crore to ₹ 39.11 crore over 7 quarters. This represents a CAGR of -36.20% The net profit of Tatva Chintan Pharma Chem Ltd changed from ₹ 5.21 crore to ₹ 15.17 crore over 7 quarters. This represents a CAGR of 84.17% The Dividend Payout of Epigral Ltd changed from 5.88 % on March 2023 to 7.26 % on March 2025 . This represents a CAGR of 7.28% over 3 yearsThe Dividend Payout of Tatva Chintan Pharma Chem Ltd changed from 19.56 % on March 2021 to 708.79 % on March 2025 . This represents a CAGR of 105.04% over 5 years .

About Epigral Ltd

Epigral Limited was erstwhile incorporated as 'Meghmani Finechem Limited' in 2007, which is engaged in manufacturing and selling of Chlor Alkali & its Derivatives and also in Trading of Agrochemical products.
The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern, through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021.
The Chlor-Alkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21.
The Company is now among the leading players in India's chlor alkali industry.
In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/- each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.

About Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Limited was formerly incorporated as 'Tatva Chintan Pharma Chem Private Limited' on 12 June 1996.
The status of the Company converted from Private Limited into a Public Limited Company from 27 January 2021 and the name of Company changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'.
The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is a globally recognized specialty chemical player with several market leading products in its portfolio.
The Company is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC).

FAQs for the comparison of Epigral Ltd and Tatva Chintan Pharma Chem Ltd

Which company has a larger market capitalization, Epigral Ltd or Tatva Chintan Pharma Chem Ltd?

Market cap of Epigral Ltd is 3,694 Cr while Market cap of Tatva Chintan Pharma Chem Ltd is 2,766 Cr

What are the key factors driving the stock performance of Epigral Ltd and Tatva Chintan Pharma Chem Ltd?

The stock performance of Epigral Ltd and Tatva Chintan Pharma Chem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Epigral Ltd and Tatva Chintan Pharma Chem Ltd?

As of March 18, 2026, the Epigral Ltd stock price is INR ₹856.45. On the other hand, Tatva Chintan Pharma Chem Ltd stock price is INR ₹1182.85.

How do dividend payouts of Epigral Ltd and Tatva Chintan Pharma Chem Ltd compare?

To compare the dividend payouts of Epigral Ltd and Tatva Chintan Pharma Chem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.